-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-219 in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-219 in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-219 in Recurrent Head And Neck Squamous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Tipiracil Hydrochloride + Trifluridine) in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Tipiracil Hydrochloride + Trifluridine) in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Tipiracil Hydrochloride + Trifluridine) in Metastatic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-24 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-24 in Pancreatic Ductal Adenocarcinoma Drug Details: CM-24 is under development for pancreatic cancer, melanoma, ovarian cancer,...
-
Product Insights
Papillary Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Papillary Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Papillary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRTX-0902 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MRTX-0902 in Colorectal Cancer Drug Details: MRTX-0902 is under development for the treatment of solid...